Clinical Trials - March 26, 2021
Promising preclinical results from Kancera
The research results show that the company’s Fractalkine blockers have the potential to disrupt cancer cells’ resistance to chemotherapy and thereby significantly improve the treatment of advanced cancer such as ovarian cancer. Kancera is now planning for clinical preparatory studies with the aim of defining an optimal dosing strategy for the Fractalkine blocker KAND567, the […]
Clinical Trials - October 28, 2020
Kancera donates chemical library to SciLifeLab and initiates drug development collaboration
Kancera is donating a chemical library to the national research infrastructure, Chemical Biology Consortium Sweden (CBCS), at SciLifeLab, in order to support national drug development and the study of disease biology. A collaboration between Kancera and CBCS is also being initiated, which gives Kancera the opportunity to identify new drug candidates for future drug development. […]
COVID-19 - May 20, 2020
Kancera applies for Phase II study in COVID-19 patients
The company has submitted an application to the Swedish Medicines Agency for permission to conduct a phase II clinical study of the drug candidate KAND567 in COVID-19 patients. The ultimate goal of clinical development is to curb hyperinflammation and thus avoid intensive care treatment and long-term rehabilitation for patients with COVID-19. The study is intended […]
Pharma Business - May 2, 2016
Kancera acquires Fractalkine project
Swedish Kancera is to acquire Fractalkine project from Acturum Life Science and the payment for is to be carried in three steps with total of 6 million shares. Due to positive efficacy data in disease models of cancer and pain, Kancera’s Board of Directors has decided to exercise the exclusive option to acquire the Fractalkine project. Kancera […]
Clinical Trials - October 3, 2014
Kancera gives update on ROR project
Preliminary results from an initial efficacy study show that molecule inhibitor KAN0439834 reduced the number of ROR-expressing leukemia cells. Kancera has completed an initial efficacy study of KAN0439834 (a small molecule inhibitor of ROR1) in an animal model of chronic lymphocytic leukemia. Preliminary results show that KAN0439834 reduces the number of ROR-expressing leukemia cells after 7 days of treatment […]
Drug Development Pharma - August 12, 2014
Kancera gets additional funding
Research company Kancera has received a final grant to one of the company’s cancer projects. The grant is given by the Swedish innovation authority Vinnova which has identified Kancera as a young innovative company with growth potential. The company develops new treatment methods for cancer and their ROR project has been allocated another SEK 500 […]
